Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Nam AS, Chaligne R, Landau DA. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nat Rev Genet. 2021;22(1):3-18.

Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.

Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, et al. Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ Precis Oncol. 2021;5(1):44.

Pan PC, Pisapia DJ, Ramakrishna R, Schwartz TH, Pannullo SC, Knisely JP, et al. Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center. Neurooncol Adv. 2021;3(1):vdab094.

Frank SM, Cushing MM. Bleeding, anaemia, and transfusion: an ounce of prevention is worth a pound of cure. Br J Anaesth. 2021;126(1):5-9.

Pena MD, Canete-Portillo S, Amin A, Aron M, Colombo P, Cox R, et al. Testicular Germ-Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience. Mod Pathol. 2021.

Riyahi S, Dev H, Blumenfeld JD, Rennert H, Yin X, Attari H, et al. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease. J Magn Reson Imaging. 2021;53(2):564-576.

Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, et al. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance. 2021;4(2).

Patel A, Hoda SA, Swistel AJ. Mammary myofibroblastoma in a male: A classic case. Breast J. 2021;27(2):181-182.

Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, et al. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. Am J Surg Pathol. 2021;45(3):384-393.